Related Experiment Video
Updated: Jan 3, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
Published on: April 26, 2017
Differential Functions of Splicing Factors in Mammary Transformation and Breast Cancer Metastasis
SungHee Park1, Mattia Brugiolo1, Martin Akerman2
1The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Abstract:
Misregulation of alternative splicing is a hallmark of human tumors, yet to what extent and how it contributes to malignancy are only beginning to be unraveled. Here, we define which members of the splicing factor SR and SR-like families contribute to breast cancer and uncover differences and redundancies in their targets and biological functions. We identify splicing factors frequently altered in human breast tumors and assay their oncogenic functions using breast organoid models. We demonstrate that not all splicing factors affect mammary tumorigenesis in MCF-10A cells. Specifically, the upregulation of SRSF4, SRSF6, or TRA2β disrupts acinar morphogenesis and promotes cell proliferation and invasion in MCF-10A cells. By characterizing the targets of these oncogenic splicing factors, we identify shared spliced isoforms associated with well-established cancer hallmarks. Finally, we demonstrate that TRA2β is regulated by the MYC oncogene, plays a role in metastasis maintenance in vivo, and its levels correlate with breast cancer patient survival.
Insights
Alternative splicing factors SRSF4, SRSF6, and TRA2β promote breast cancer by disrupting cell structure and increasing invasion. TRA2β, regulated by MYC, is linked to metastasis and patient survival.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Alternative splicing misregulation is common in human tumors.
- The specific roles of splicing factors in breast cancer are not fully understood.
Purpose of the Study:
- Identify splicing factors involved in breast cancer.
- Investigate their oncogenic functions and targets.
- Determine the role of TRA2β in metastasis and patient survival.
Main Methods:
- Analysis of splicing factor alterations in human breast tumors.
- Utilizing breast organoid models (MCF-10A) to assay oncogenic functions.
- Characterization of shared spliced isoforms and MYC regulation of TRA2β.
Main Results:
- SRSF4, SRSF6, and TRA2β upregulation promotes breast cancer progression in vitro.
- These factors target shared spliced isoforms linked to cancer hallmarks.
- TRA2β is regulated by MYC, supports metastasis in vivo, and correlates with patient survival.
Conclusions:
- Specific SR and SR-like splicing factors drive breast cancer progression.
- TRA2β is a MYC-regulated oncogenic factor with prognostic value in breast cancer.
Related Concept Videos
RNA Splicing
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

